Takeda offloads URL generics business to Caraco for $65m
This article was originally published in Scrip
In a move expected since it completed the acquisition of the private US firm in June, Takeda is divesting the generics business of URL Pharma, with the Caraco Pharmaceutical Laboratories subsidiary of India's Sun Pharmaceutical Industries emerging as the buyer.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.